We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic factors and Doxorubicin involved in malignant progression of meningioma.
- Authors
Huo, Xulei; Song, Lairong; Wang, Ke; Wang, Hongyi; Li, Da; Li, Huan; Wang, Wei; Wang, Yali; Chen, Lei; Zhao, Zongmao; Wang, Liang; Wu, Zhen
- Abstract
Meningioma was the most primary intracranial tumor, but the molecular characteristics and the treatment of malignant meningioma were still unclear. Nine malignant progression-related genes based prognostic signatures were identified by transcriptome analysis between benign meningioma and malignant meningioma. The external dataset GEO136661 and quantitative Real-time Polymerase Chain Reaction were used to verify the prognostic factors. has-miR-3605-5p, hsa-miR-664b-5p, PNRC2, BTBD8, EXTL2, SLFN13, DGKD, NSD2, and BVES were closed with malignant progression. Moreover, Doxorubicin was identified by Connectivity Map website with the differential malignant progression-related genes. CCK-8 assay, Edu assay, wound healing assay, and trans-well experiment were used to reveal that Doxorubicin could inhibit proliferation, migration and invasion of IOMM-Lee Cells.
- Subjects
PROGNOSIS; MENINGIOMA; INTRACRANIAL tumors; POLYMERASE chain reaction
- Publication
Scientific Reports, 2023, Vol 13, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-023-28996-0